KORU Medical Systems Reports Outstanding Performance in 2024
KORU Medical Systems (NASDAQ: KRMD) has recently shared impressive preliminary results for their fourth quarter and full year of 2024. As a prominent player in the medical technology field, the company focuses on innovative solutions for large volume subcutaneous infusion. With a remarkable net revenue of approximately $8.9 million for the fourth quarter alone, KORU Medical has experienced significant growth of 23% compared to the same period last year.
Strong Annual Growth and Cash Flow Highlights
For the complete year, KORU Medical forecasts net revenues reaching around $33.7 million, marking a substantial increase of 18% year-over-year. This outstanding performance also includes a notable cash balance of $9.6 million, representing a positive cash flow of $0.8 million in the fourth quarter. These results demonstrate a remarkable 67% improvement in cash burn from the prior year, showcasing the company's careful management and strategic execution.
Corporate Strategy and Market Development
Linda Tharby, President and CEO of KORU Medical, expressed her pride in the company’s achievements, commenting, "We executed on all aspects of our strategic plan as we continued to win share in the US market and expanded our international footprint. This progress is accompanied by efforts to add new drug therapies to our label, which positions us favorably for future growth. Our improved margins and disciplined cash use further enhance our readiness for upcoming opportunities."
Commitment to Patient-Centric Solutions
KORU Medical’s dedication to enhancing patient experiences is evident in their innovative solutions. The FREEDOM Syringe Infusion System, which has been delivering exceptional results since its FDA clearance in 1994, enables patients to self-administer therapy in a comfortable home environment or receive care in an ambulatory infusion center. This flexibility is key in improving patients' quality of life throughout their treatment journeys.
Upcoming Financial Announcements
The company plans to fully disclose its fourth quarter and annual financial results in early March 2025. While preliminary figures are very promising, they remain subject to adjustments after the review by independent auditors.
Expansion Through Novel Therapies
KORU Medical’s Novel Therapies division plays a crucial role in tailoring solutions for biopharmaceutical companies. During clinical trials, KORU Medical provides essential products and adapts the Freedom System according to the unique needs of various drug categories. This approach solidifies their position as a vital partner in the drug development process.
Looking Ahead
As KORU Medical moves into 2025, the company is enthusiastic about leveraging its strong momentum. With continued support from ongoing growth strategies and market expansion, KORU aims to solidify its status as a global leader in drug delivery systems.
Frequently Asked Questions
What were KORU Medical's revenue results for 2024?
KORU Medical reported preliminary revenues of $33.7 million for 2024, indicating an 18% growth over the previous year.
How much cash flow did KORU Medical achieve in Q4 2024?
The company experienced positive cash flow of $0.8 million for the fourth quarter of 2024.
What is the FREEDOM Syringe Infusion System?
The FREEDOM Syringe Infusion System is an innovative solution for large volume subcutaneous infusion, enabling self-administration by patients or professional care in ambulatory infusion centers.
When will KORU Medical release its full financial results?
KORU Medical plans to release its comprehensive fourth quarter and annual financial results in early March 2025.
How does KORU Medical support drug development?
Through its Novel Therapies division, KORU Medical supplies products for clinical trials, customizing solutions for different drug categories as needed.
